Global Oncology Partnering Deal Trends, Players and Financials 2010-2017

Dublin, Oct. 27, 2017 -- The "Global Oncology Partnering 2010-2017: Deal trends, players and financials" report has been added to Research and Markets' offering.

The Global Oncology Partnering 2010-2017: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

In addition, a comprehensive appendix is provided with each report of all Oncology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Report scope

• Trends in oncology dealmaking in the biopharma industry since 2010
• Analysis of oncology deal structure
• Access to headline, upfront, milestone and royalty data
• Access to over 3,500 oncology deal records
• The leading oncology deals by value since 2010

The report includes deals for the following indications:

• Oral mucositis
• Cancer pain
• Bone
• Neuropathic
• Muscular
• Lymphoedema
• Alopecia
• Cachexia
• Ulcers
• Dysphagia
• Tiredness
• Weight loss
• Nausea
• Vomiting
• Chemotherapy
• Radiotherapy
• Adenocarcinoma
• Basal cell carcinoma
• Bile duct cancer
• Bladder cancer
• Bone cancer
• Brain cancer
• Breast cancer
• Cervical cancer
• Colorectal cancer
• Endometrial
• Esophageal cancer
• Gastric cancer
• Head and neck cancer
• Kaposi's sarcoma
• Kidney cancer
• Leukemia
• Acute lymphoblastic leukemia
• Acute myelogenous leukemia
• Chronic lymphocytic leukemia
• Chronic myelogenous leukemia
• Liver cancer
• Lung cancer
• Small cell lung cancer
• Non small cell lung cancer
• Lymphoma
• Hodgkin's lymphoma
• Non Hodgkin's lymphoma
• Melanoma
• Mesothelioma
• Metastases
• Bone metastases
• Multiple myeloma
• Neuroblastoma
• Non-melanoma skin cancer
• Ovarian cancer
• Pancreatic cancer
• Prostate cancer
• Renal cell carcinoma
• Sarcoma
• Solid tumors
• Testicular cancer
• Thyroid cancer

In Global Oncology Partnering 2010-2017: Deal trends, players and financials, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
  

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Oncology dealmaking

Chapter 3 Financial deal terms for Oncology partnering

Chapter 4 Leading Oncology deals and dealmakers

Chapter 5 Oncology contract document directory

Chapter 6 Oncology dealmaking by therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/d24xnf/global_oncology

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Oncology Drugs